Halozyme Therapeutics (HALO) Tops Q2 EPS by 6c
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $111.45 -0.89%
EPS Growth %: +30.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MLKN, KBH, WOR, More
EPS Growth %: +30.8%
Financial Fact:
Cost of product sales: 9.13M
Today's EPS Names:
MLKN, KBH, WOR, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $29.94 million.
GUIDANCE:
Halozyme Therapeutics sees FY2016 revenue of $140-150 million, versus prior guidance of $130-145 million and the consensus of $136.7 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Deutsche Bank Upgrades Danone SA (BN:FP) (DANOY) to Hold
- HP Inc. projects mid-single-digit PC market decline in 2027
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
